gastroparesis and glp 1 drugs GLP-1 Gastroparesis: What Patients Should Know? The GLP-1 Agonists and Obesity:

Originally designed to treat type 2 diabetes, these medications are now approved for weight management due to their impressive results in promoting healthy, sustainable weight loss

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials

lower cardiovascular risk)

Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is similar to existing weight loss medications like tirzepatide and semaglutide but has increased efficacy

198,205,206 GLP-1 can also enhance the uptake and utilization of glucose in muscle and adipose tissues